Brought to you by 
Micromet grosses $40mm privately
17 Oct 2008
Executive Summary
Micromet (cancer, inflammation, and autoimmune disease antibodies) has grossed $40mm through the private sale of 9.4mm common shares at $4.25 each (an 8% discount). Investors also received five-year warrants to buy another 2.8mm shares at $4.63 apiece. Index Ventures Growth, Abingworth, DAFNA Capital Management, and Merlin Nexus participated and were joined by three Micromet directors and two funds affiliated with the members. The company will use the funds to continue clinical development of its antibodies, including BiTE blinatumomab (MT103/MEDI538) in Phase II for acute lympoblastic leukemia and in Phase I for non-Hodgkin's lymphoma. Piper Jaffray and RBC Capital Markets were the placement agents.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Micromet grosses $40mm privately
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice